0001809616 2026-09-26 2026-09-26 0001809616 1 2026-09-26 2026-09-26 0001809616 2 2026-09-26 2026-09-26 0001809616 3 2026-09-26 2026-09-26 0001809616 4 2026-09-26 2026-09-26 0001809616 5 2026-09-26 2026-09-26 0001809616 6 2026-09-26 2026-09-26 0001809616 7 2026-09-26 2026-09-26 0001809616 8 2026-09-26 2026-09-26 0001809616 1 2026-09-26 2026-09-26 0001809616 2 2026-09-26 2026-09-26 iso4217:USD pure shares F-3 F-3 EX-FILING FEES 0001809616 Universe Pharmaceuticals INC N/A 0.0001381 true false F-3 Universe Pharmaceuticals INC false Equity Class A Ordinary Shares true 0 0.00 0.00 0.0001381 0.00 false Debt Debt Securities true 0 0.00 0.00 0.0001381 0.00 false Other Warrants true 0 0.00 0.00 0.0001381 0.00 false Other Rights true 0 0.00 0.00 0.0001381 0.00 false Other Units true 0 0.00 0.00 0.0001381 0.00 false Other Unallocated (Universal) Shelf true 200000000.00 false Unallocated (Universal) Shelf true 200000000.00 0.0001381 27620.00 false Equity Class A Ordinary Shares true 4376552 4.71 20613559.92 0.0001381 2846.73 220613559.92 30466.73 0.00 21112.27 9354.46 There are being registered hereunder such indeterminate number of Class A ordinary shares, debt securities, warrants, rights, and units as shall have an aggregate initial offering price not to exceed $200,000,000. Any securities registered hereunder may be sold separately or in combination with other securities registered hereunder. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares being registered hereunder also include such indeterminate number of shares as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends, or similar transactions. The proposed maximum per unit and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified pursuant to Instruction 2.A.ii.b. to the Calculation of Filing Fee Tables and Related Disclosure of Item 9(b) of Form F-3 under the Securities Act. Represents up to 4,376,552 Class A ordinary shares of the Registrant to be offered and sold by the selling shareholders identified in the prospectus. This estimate is made pursuant to Rule 457(c) of the Securities Act, solely for purposes of calculating the registration fee. The proposed maximum offering price is calculated on the average of the high ($4.805) and low ($4.61) prices for the Registrant's ordinary shares as listed on the Nasdaq Capital Market on September 24, 2026. true Universe Pharmaceuticals INC F-3 333-268028 2022-10-27 21112.27 Unallocated (Universal) Shelf 0 0 191581386.00 true Universe Pharmaceuticals INC F-3 333-268028 2022-10-27 21112.27 In accordance with Rule 457(p) under the Securities Act, the registrant is offsetting $21,112.27 of the fee associated with this registration statement from the fee previously paid by the registrant associated with the unsold securities registered under the registrant's prior unallocated (universal) shelf registration statement on Form F-3 originally filed on October 27, 2022 (File No. 333-268028) (the "Prior Registration Statement"), which has expired because more than three years have elapsed since the initial effective date of the Prior Registration Statement and all offerings thereunder have been completed or terminated. $191,581,386 of aggregate maximum amount remain unsold as of the time the Prior Registration Statement expired. In accordance with Rule 457(p) under the Securities Act, the registrant is offsetting $21,112.27 of the fee associated with this registration statement from the fee previously paid by the registrant associated with the unsold securities registered under the Prior Registration Statement, which has expired because more than three years have elapsed since the initial effective date of the Prior Registration Statement and all offerings thereunder have been completed or terminated. $191,581,386 of aggregate maximum amount remain unsold as of the time the Prior Registration Statement expired.